Table 2 |
||||||||||
|
Clinical characteristics of family 310. The patient number refers to the number in the pedigree in Figure 1. |
||||||||||
|
Patient |
Cancer |
Histology |
Age at diagnosis |
Reason for diagnosis |
First treatment |
Primary PSA value |
WHO grading |
Gleason grading |
TNM grading |
IHC |
|
|
||||||||||
|
6 |
Prostate |
Adenocarcinoma |
83 |
NA |
NA |
NA |
NA |
NA |
NA |
|
|
11 |
Prostate |
Adenocarcinoma |
68 |
Symptoms |
Orchiectomy |
NA |
III |
Na |
T3NXMX |
|
|
13 |
Stomach |
Adenocarcinoma |
70 |
Symptoms |
Gastrectomy |
NA |
NA |
Na |
T4N0 M0 |
|
|
13 |
Skin |
Carcinoma epidermoides |
75 |
NA |
Resection |
NA |
NA |
Na |
NA |
|
|
13 |
Prostate |
Adenocarcinoma |
76 |
Elevated PSA |
Orchiectomy |
47 |
III |
2+3 = 5 |
T2NXMX |
|
|
15 |
Prostate |
Adenocarcinoma |
69 |
Elevated PSA |
Brakytherapy |
7.7 |
I |
2+3 = 5 |
T1cNXMX |
|
|
17 |
Breast |
Ductal carcinoma |
52 |
Screening mammography |
Mammary resection |
NA |
I |
Na |
T1N0 M0 |
ER+, PR+ |
|
24 |
Breast |
Ductal carcinoma |
49 |
Mammography |
Mammary resection |
NA |
I |
Na |
T1N0 M0 |
NA |
|
|
||||||||||
|
IHC = immunohistochemistry, NA = not available |
||||||||||
|
Pakkanen et al. Journal of Negative Results in BioMedicine 2009 8:12 doi:10.1186/1477-5751-8-12 |
||||||||||
